Clinical Study of I-DXd Compared to Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Résumé de l'étude
This Phase 3 study investigates the efficacy and safety of the drug I-DXd compared to Docetaxel (standard therapy) in patients with advanced castration-resistant prostate cancer (www.clinicaltrialsregister.eu; number 2024-517423-40). • Ifinatamab Deruxtecan (I-DXd) is an antibody-drug conjugate consisting of an antibody and chemotherapy. The antibody targets a protein on tumor cells, allowing the drug to directly reach and enter these tumor cells while largely sparing healthy cells. This aims to reduce the side effects of chemotherapy while effectively combating tumor cells. • Docetaxel is a chemotherapy that works by inhibiting the growth and division of cancer cells. Docetaxel is typically administered intravenously and can help slow disease progression and reduce tumor size. Approximately 1440 patients are expected to participate in this study worldwide, with about 20 from Switzerland. The total study duration is approximately 5.5 years.
(BASEC)
Intervention étudiée
After thorough information, detailed eligibility assessment, medical history collection, and comprehensive explanation, participants will be included in the study and randomly assigned to one of the two treatment groups.
Group 1: Ifinatamab Deruxtecan (I-DXd)
Group 2: Docetaxel + Prednisone/Prednisolone
The probability of being assigned to Group 1 or 2 is equal, and both participants and study doctors know which treatment is being administered.
After a screening phase of up to 6 weeks (42 days), each participant receives the assigned treatment. Participants in Group 1 receive treatment with I-DXd as long as the cancer does not worsen and the tested drug is well tolerated. Participants in Group 2 receive treatment with Docetaxel for up to about 7 months as long as the cancer does not worsen and the drug is well tolerated. The respective study drug is administered once on the first day of a 21-day treatment cycle via infusion.
After completing the treatment, participants will be monitored for a certain period.
During study visits, various measures and examinations may occur, e.g.: imaging procedures such as CT and MRI (computed or magnetic resonance imaging), electrocardiogram (ECG) - an examination to check the electrical activity of your heart, MUGA scans or echocardiogram (ECHO) - both examinations to assess your heart function, blood and urine tests, tumor biopsies, eye examinations, physical examinations including checking vital signs (pulse, blood pressure, etc.), answering questionnaires.
(BASEC)
Maladie en cours d'investigation
Prostate cancer is the most common cancer in men in Switzerland and Europe and the fifth leading cause of death. The disease usually occurs after the age of 65. Initially, the cancer grows slowly and often goes undetected. When prostate disease spreads to other parts of the body, it is referred to as advanced (metastatic) prostate cancer. While many men diagnosed with localized disease can be treated with radiation therapy or surgical procedures, those who develop metastatic prostate cancer are typically first treated with androgen deprivation therapy. Androgen deprivation therapy, or ADT, is a hormonal withdrawal treatment that can often control the disease for many years. If prostate cancer progresses despite this therapy, it is referred to as metastatic castration-resistant (mCRPC). Additional treatments must be used, such as androgen receptor pathway inhibitors (ARPI) or chemotherapy (e.g., Docetaxel). Currently, there is an urgent medical need for new treatment options that are more effective, delay disease progression, improve survival, and maintain quality of life.
(BASEC)
• Confirmed diagnosis of metastatic prostate cancer • Disease progression during androgen deprivation therapy or during therapy with androgen receptor pathway inhibitors (ARPI) • Participants must have recovered from side effects caused by previous cancer medications. (BASEC)
Critères d'exclusion
• Previous treatment with cancer medications such as Orlotamab, Enoblituzumab, or other B7-H3 targeted agents, including I-DXd • A gastrointestinal disease that affects absorption (e.g., gastrectomy or active gastric ulcer disease within the last 3 months) • Uncontrolled, significant cardiovascular disease and significant corneal disease (BASEC)
Lieu de l’étude
Aarau, Bâle, Fribourg, Genève, Zurich
(BASEC)
Sponsor
MSD Merck Sharp & Dohme AG, Lucerne, Switzerland Merck & Co., Inc., Rahway, NJ, USA
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Klaudia Georgi
+41 58 618 33 88
klaudia.georgi@cluttermsd.comMSD Merck Sharp & Dohme AG, Lucerne
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale de Zurich
(BASEC)
Date d'approbation du comité d'éthique
06.06.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01) (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible